ALRN Stock Price, Aileron Therapeutics Inc Quote, Chart

Market Summary

USD3.68-0.01

Delayedas of 08 May 2024, 02:57 pm

-0.27%

ALRN Stock Price

View Fullscreen

ALRN RSI Chart

ALRN Valuation

Market Cap

62.2M

Price/Earnings (Trailing)

-3.96

Price/Sales (Trailing)

382.26

Price/Free Cashflow

-3.14

ALRN Price/Sales (Trailing)

ALRN Profitability

Return on Equity

-228.43%

Return on Assets

-14.84%

Free Cashflow Yield

-31.82%

ALRN Fundamentals

ALRN Revenue

Revenue (TTM)

222.0K

ALRN Earnings

Earnings (TTM)

-15.7M

Earnings Growth (Yr)

-61.4%

Earnings Growth (Qtr)

-301.7%

Breaking Down ALRN Revenue

52 Week Range

1.333.76

(Low)(High)

Last 7 days

-18.9%

Last 30 days

-34.8%

Last 90 days

-17.4%

Trailing 12 Months

149.0%

How does ALRN drawdown profile look like?

ALRN Financial Health

Current Ratio

4.17

ALRN Investor Care

Shares Dilution (1Y)

271.46%

Diluted EPS (TTM)

-3.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2017	0	0	222.0K	0
2016	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aileron Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	university of texas/texas am investment management co	sold	-85,473	4.20741	-20,315	-
Apr 30, 2024	university of texas/texas am investment management co	sold	-447	4.975	-90.00	-
Apr 29, 2024	university of texas/texas am investment management co	sold	-53,181	4.94898	-10,746	-
Mar 05, 2024	windsor james brian	acquired	-	-	2,000	president and coo
Dec 15, 2023	windsor james brian	bought	758	3.37	225	president and coo
Nov 20, 2023	windsor james brian	bought	9,987	1.9675	5,076	president and coo
Jan 08, 2021	satter muneer a	bought	9,900,000	1.1	9,000,000	see remarks

Which funds bought or sold ALRN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	Sigma Planning Corp	added	310	400,195	450,741	0.01%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	JFS WEALTH ADVISORS, LLC	unchanged	-	5,694	10,542	-%
Apr 12, 2024	Game Plan Financial Advisors, LLC	unchanged	-	180	332	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.95	62,201	122,901	-%
Mar 08, 2024	ICA Group Wealth Management, LLC	new	-	305	305	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	191	381	-%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	sold off	-100	-30,434	-	-%
Feb 14, 2024	GAGNON SECURITIES LLC	new	-	115,685	115,685	0.03%
Feb 13, 2024	Tower Research Capital LLC (TRC)	reduced	-50.63	-67.00	6,787	-%

Are Funds Buying or Selling ALRN?

Are funds buying ALRN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALRN

No. of Funds

Unveiling Aileron Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 16, 2024	satter muneer a	4.9%	830,466	SC 13D/A
Mar 05, 2024	satter muneer a	5.9%	1,017,033	SC 13D/A
Mar 05, 2024	university of texas/texas am investment managment co	6.2%	1,812,627	SC 13G
Feb 14, 2024	biotechnology value fund l p	-	0	SC 13G/A
Feb 05, 2024	kapnick scott	0%	0	SC 13G/A
Nov 13, 2023	bios fund i, lp	9.99%	539,293	SC 13G
Nov 03, 2023	satter muneer a	19.9%	1,007,488	SC 13D/A
Feb 14, 2023	biotechnology value fund l p	2.8%	125,755	SC 13G/A
Feb 14, 2023	kapnick scott	8.4%	379,608	SC 13G/A
Feb 14, 2022	kapnick scott	8.4%	7,592,222	SC 13G/A

Recent SEC filings of Aileron Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 01, 2024	4	Insider Trading
May 01, 2024	424B5	Prospectus Filed
May 01, 2024	8-K	Current Report
May 01, 2024	8-K	Current Report
May 01, 2024	FWP	Prospectus Filed
May 01, 2024	S-8	Employee Benefits Plan
Apr 30, 2024	3	Insider Trading
Apr 29, 2024	144	Notice of Insider Sale Intent
Apr 29, 2024	10-K/A	Annual Report
Apr 16, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to Aileron Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Aileron Therapeutics Inc News

Latest updates

Aileron Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2017Q3	2017Q2	2016Q3	2016Q2
Revenue	475.9%	167,000	29,000	10,000	16,000

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	726.8%	106,008	12,822	13,991	17,157	22,007	27,232	33,770	40,255	48,481	54,768	60,531	64,671	16,341	22,239	26,125	20,373	26,473	33,952	40,193	22,399	30,312
Current Assets	42.8%	18,266	12,793	13,952	17,105	21,873	27,054	33,550	39,993	48,177	54,423	60,152	64,324	16,326	15,974	19,670	13,687	19,550	26,497	32,559	14,389	21,775
Cash Equivalents	43.5%	17,313	12,069	13,167	7,783	5,194	4,839	7,628	7,449	3,600	7,603	10,748	19,283	7,046	7,850	17,124	10,697	5,311	6,867	10,157	11,272	10,635
Net PPE	-34.5%	19.00	29.00	39.00	52.00	70.00	84.00	98.00	113	128	144	153	98.00	15.00	147	164	225	295	361	379	398	7,290
Goodwill	-	6,330	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	374.8%	7,711	1,624	1,197	2,884	3,384	4,536	5,151	4,146	4,577	4,659	4,401	3,252	4,179	9,781	9,471	10,604	10,425	11,136	10,209	9,552	10,712
Current Liabilities	170.0%	4,385	1,624	1,197	2,884	3,384	4,536	5,151	4,146	4,508	4,560	4,273	3,073	3,960	5,249	4,926	6,143	5,839	6,428	5,387	4,623	5,370
Shareholder's Equity	-38.5%	6,887	11,198	12,794	14,273	18,623	22,696	28,619	36,109	43,904	50,109	56,130	61,419	12,162	12,458	16,654	9,769	16,048	22,816	29,984	12,847	19,600
Retained Earnings	-2.6%	-288,517	-281,178	-279,351	-277,564	-272,785	-268,238	-261,870	-253,878	-245,456	-238,657	-231,953	-226,267	-219,292	-214,296	-209,273	-204,883	-198,135	-190,900	-183,151	-175,979	-168,493
Additional Paid-In Capital	1.1%	295,376	292,285	292,056	291,756	291,365	290,941	290,499	289,971	289,282	288,674	287,987	287,603	231,412	226,715	225,890	214,625	214,148	213,671	213,083	188,811	188,083
Shares Outstanding	7.6%	4,886	4,541	4,541	4,541	4,541	4,539	4,537	4,534	4,529	4,411	4,347	4,169	2,190	-	-	-	-	-	-	-	-
Float	-	-	-	6,587,576	-	-	-	19,137,097	-	-	-	91,635,955	-	-	-	36,630	-	-	-	20,008	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-533.6%	-10,391	-1,640	-3,116	-4,661	-4,409	-6,971	-5,685	-7,800	-6,255	-7,260	-3,763	-6,476	-4,689	-5,043	-5,072	-5,672	-6,305	-6,976	-5,692	-7,501	-6,663
Share Based Compensation	17.9%	270	229	300	391	424	442	528	689	607	660	362	631	363	465	560	505	479	614	460	563	591
Cashflow From Investing	-117.7%	-96.00	542	8,500	7,250	4,764	4,182	5,864	11,649	2,251	4,089	-4,798	-37,459	-357	-4,529	239	11,058	4,764	3,737	-19,288	7,973	8,305
Cashflow From Financing	-	-	-	-	-	-	-	-	-	1.00	26.00	26.00	55,604	4,242	298	11,260	-	-15.00	-51.00	23,865	165	1,277

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALRN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 0	$ 0
Operating expenses:
Research and development	3,991	17,967
General and administrative	11,357	9,680
Restructuring and other costs	928
Total operating expenses	16,276	27,647
Loss from operations	(16,276)	(27,647)
Other income (expense), net	544	318
Net loss	$ (15,732)	$ (27,329)
Net loss per share - basic	$ (3.42)	$ (6.02)
Net loss per share - diluted	$ (3.42)	$ (6.02)
Weighted average common shares outstanding - basic	4,598,715	4,539,318
Weighted average common shares outstanding - diluted	4,598,715	4,539,318
Comprehensive loss:
Net Income (Loss)	$ (15,732)	$ (27,329)
Other comprehensive gain (loss):
Unrealized gain on short-term investments, net of tax of $0	48	(35)
Foreign currency translation adjustments	(63)
Total other comprehensive loss	(15)	(35)
Total comprehensive loss	$ (15,747)	$ (27,364)

ALRN Balance Sheet

2023-12-31

Consolidated balance sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 17,313	$ 5,194
Investments		16,048
Prepaid expenses and other current assets	882	606
Restricted cash	25	25
Operating lease, right-of-use asset, current portion	46
Total current assets	18,266	21,873
Operating lease, right-of-use asset		40
Property and equipment, net	19	70
Goodwill	6,330
Intangible assets	79,200
Other non-current assets	2,193	24
Total assets	106,008	22,007
Current liabilities:
Accounts payable	1,190	1,720
Accrued expenses and other current liabilities	3,147	1,631
Operating lease liabilities, current portion	48	33
Total current liabilities	4,385	3,384
Deferred tax liability	3,326
Total liabilities	7,711	3,384
Commitments and contingencies (Note 15)
Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized at December 31, 2023 and at December 31, 2022; 24,610 shares issued and outstanding at December 31,2023 and no shares issued and outstanding at December 31,2022	91,410
Stockholders’ equity:
Common stock, $0.001 par value; 45,000,000 shares authorized at December 31, 2023 and December 31, 2022; 4,885,512 shares and 4,541,167 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	91	91
Additional paid-in capital	295,376	291,365
Accumulated other comprehensive loss	(63)	(48)
Accumulated deficit	(288,517)	(272,785)
Total stockholders’ equity	6,887	18,623
Total liabilities, convertible preferred stock and stockholders' equity	$ 106,008	$ 22,007

About Aileron Therapeutics Inc

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

CEO	Dr. Manuel C. Aivado M.D., Ph.D.
WEBSITE	aileronrx.com
INDUSTRY	Biotechnology
EMPLOYEES	6

Aileron Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aileron Therapeutics Inc? What does ALRN stand for in stocks?

ALRN is the stock ticker symbol of Aileron Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aileron Therapeutics Inc (ALRN)?

As of Tue May 07 2024, market cap of Aileron Therapeutics Inc is 62.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALRN stock?

You can check ALRN's fair value in chart for subscribers.

What is the fair value of ALRN stock?

You can check ALRN's fair value in chart for subscribers. The fair value of Aileron Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aileron Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALRN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aileron Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALRN is over valued or under valued. Whether Aileron Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aileron Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALRN.

What is Aileron Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, ALRN's PE ratio (Price to Earnings) is -3.96 and Price to Sales (PS) ratio is 382.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALRN PE ratio will change depending on the future growth rate expectations of investors.